Drugmakers Zydus Cadila said it has received the approval from the Drugs Controller General of India (DCGI) to start phase 3 clinical trials with its biological therapy PegiHep in COVID-19 patients’ company is going to start phase 3 trials with PegiHep soon. The trials will start in December in the start it will be conducted on 250 patients across 20-25centres in India.The company is going to start further trials a similar phase 2 in Mexico and the US Food and Drug Administration (USFDA) to start the Investigational New Drug(IND) application for Pegylated Interferon alpha-2b in order to initiate appropriate clinical trials in US.
In an unconventional and ethically charged move, Beata Halassy, a virologist at the University of…
Millets have gained a reputation as a superfood in recent years, celebrated for their nutritional…
Protein is one of the most essential nutrients our body needs to maintain overall health…
Menopause is a significant life transition for many women, marked by the end of menstrual…
In a remarkable instance of medical intervention, doctors in a Delhi hospital successfully saved the…
Pneumonia, an infection that inflames the air sacs in one or both lungs, is often…